Picture of Oxford BioMedica logo

OXB Oxford BioMedica News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

REG - Oxford Biomedica PLC - Grant of options




 



RNS Number : 2108B
Oxford Biomedica PLC
08 June 2021
 

Grant of options

 

London, UK - 08 June 2021: Oxford Biomedica plc ("Oxford Biomedica" or the "Company") (LSE:OXB), a leading gene and cell therapy group announces that on 08 June 2021 nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the Oxford Biomedica 2015 Deferred Bonus Plan ("DBP") and the Oxford Biomedica 2015 Long Term Incentive Plan ("LTIP").

 

2021 LTIP Awards

 

Name of individual

Title

Number of shares subject to the 2021 DBP award

Number of shares subject to the 2021 LTIP award

Total shares over which options now held

Percentage of current issued share capital under option

John Dawson

Chief Executive Officer

20,221

80,460

848,393

1.0%

Stuart Paynter

Chief Financial Officer

11,642

47,966

247,902

0.3%

James Miskin

Chief Technical Officer

4,897

18,943

154,914

0.2%

Kyriacos Mitrophanous

Chief Scientific Officer

4,944

19,125

171,545

0.2%

Nick Page

Chief Operations Officer

5,170

19,999

89,436

0.1%

Helen Stephenson-Ellis

Chief People Officer

3,331

13,131

75,758

0.09%

Jason Slingsby

Chief Business Officer

4,595

18,114

108,867

0.1%

Natalie Walter

General Counsel

4,143

16,028

66,905

0.08%

 

Under the terms of the  DBP, the DBP awards will become exercisable as to one third of the shares subject to each award on each of the first three anniversaries of the grant date.

 

The LTIP awards are subject to performance conditions. As set out in the 2020 Directors' Remuneration Report, the performance condition is based on TSR (40% of the award, assessed over the three years from grant); revenue growth (40% of the award, assessed over financial years 2021, 2022 and 2023) and strategic milestones (20% of the award). Details of the measures are included in the 2020 Directors' Remuneration Report, other than as regards the strategic milestones, which are commercially sensitive and will be disclosed in due course.

 

The LTIP awards granted to John Dawson and Stuart Paynter will "vest" following the assessment of the performance condition, but will only be "released" so that they can be exercised following the end of a further two year holding period. The2021 awards granted to other participants will vest and be released following the assessment of the performance condition.

 

The above table reflects the grant of an award (1,320) to rectify an administrative error in the 2020 LTIP award granted to the General Counsel and the lapse of an award (7,875) to rectify an administrative error in the 2020 LTIP award granted to the Chief Financial Officer ("CFO") on 26 June 2020.  These amendments were also reflected in the Company's 2020 Report & Accounts. 

 

RSU awards

 

In addition, on 08 June 2021 a nil-cost share option over 4,406 shares of 50 pence each in the Company was also granted under the LTIP scheme to Alexander Lewis, Chief of Staff. The RSU award is not subject to performance conditions and will become exercisable from the third anniversary of the grant date. The total shares over which options are held by Alexander Lewis is 69,227, representing 0.08% of the current issued share capital under option.

 

The current issued share capital of the Company is 82,555,443 ordinary shares of 50 pence each.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

John Dawson

2.

Reason for the notification

a)

Position/status

Chief Executive Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2021 LTIP Award

 

Price

Volume

Nil

80,460

 

2021 DBP Award

 

Price

Volume

Nil

20,221

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 100,681 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Stuart Paynter

2.

Reason for the notification

a)

Position/status

Chief Financial Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2021 LTIP Award

 

Price

Volume

Nil

47,966

 

2021 DBP Award

 

Price

Volume

Nil

11,642

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 59,608 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2021 LTIP Award

 

Price

Volume

Nil

18,943

 

2021 DBP Award

 

Price

Volume

Nil

4,897

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 23,840 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Kyriacos Mitrophanous

2.

Reason for the notification

a)

Position/status

Chief Scientific Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2021 LTIP Award

 

Price

Volume

Nil

19,125

 

2021 DBP Award

 

Price

Volume

Nil

4,944

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 24,069 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Nick Page

2.

Reason for the notification

a)

Position/status

Chief Operations Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2021 LTIP Award

 

Price

Volume

Nil

19,999

 

2021 DBP Award

 

Price

Volume

Nil

5,170

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 25,169 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Helen Stephenson-Ellis

2.

Reason for the notification

a)

Position/status

Chief People Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2020 LTIP Award

 

Price

Volume

Nil

13,131

 

2021 DBP Award

 

Price

Volume

Nil

3,331

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 16,462 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Jason Slingsby

2.

Reason for the notification

a)

Position/status

Chief Business Officer

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2021 LTIP Award

 

Price

Volume

Nil

18,114

 

 

 

 

2021 DBP Award

 

Price

Volume

Nil

4,595

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 22,709 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Natalie Walter

2.

Reason for the notification

a)

Position/status

General Counsel

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan and Deferred Bonus Plan. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2020 LTIP Award

 

Price

Volume

Nil

16,028

 

2021 DBP Award

 

Price

Volume

Nil

4,143

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

Awards granted over 20,171 shares in total

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 



 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Alexander Lewis

2.

Reason for the notification

a)

Position/status

Chief of Staff

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 50 pence each

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Grant of award over Ordinary Shares under the Company's Executive Share Option Scheme. No consideration was paid for the grant of awards.

c)

Price(s) and volumes(s)

2021 RSU Award

 

Price

Volume

Nil

4,406

 

 

 

d)

Aggregated information

-    Aggregate volume

 

-    Price

 

 

4,406

 

 

N/A

 

e)

Date of the transaction

2021-06-08

f)

Place of the transaction

Outside of trading venue

 

-Ends-

 

For further information, please contact:

 

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFZGGVFRMGMZM

Recent news on Oxford BioMedica

See all news